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Abstract Florbetaben is a fluorine-18 (18F)-labeled stil-
bene derivative that was developed as a positron emission
tomography (PET) tracer for routine clinical application to
visualize b-amyloid plaques in the Alzheimer’s disease
(AD) brain. The tracer successfully completed a global
multicenter phase 0–III development program and was, as a
consequence, recently approved by the US Food and Drug
Administration and the European Medicines Agency. This
review provides an overview on the florbetaben tracer
characteristics and preclinical data leading to its human
testing. Further, the favorable results of human pharma-
cokinetics, safety, and dosimetry evaluation of florbetaben
are presented. Next, the results of the clinical testing of
florbetaben are discussed, in which the tracer was shown to
sensitively and specifically detect b-amyloid neuritic pla-
ques, as evidenced by employing different gold standards
(from clinical diagnosis to post mortem histopathology).
The potential of florbetaben to predict AD dementia in
cases of mild cognitive impairment and to assist in the
differential diagnosis in cases of dementia is also de-
scribed. Finally, potential clinical impact and clinical
routine PET image acquisition and analysis protocols for
florbetaben are discussed. Taken together, the evidence
shows that florbetaben is a valuable b-amyloid-targeting
PET tracer in the clinic with great potential to serve as a
biomarker supporting clinical AD diagnosis.
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Introduction
The deposition of b-amyloid is considered one of the initial
events in the pathogenesis of Alzheimer’s disease (AD) [1],
and most likely begins years before the initial onset of
detectable cognitive symptoms, followed by gradual pro-
gression [2]. So far, however, cerebral b-amyloid plaques
are only detectable in postmortem histopathology, which
excludes this approach from establishment as a diagnostic
tool during lifetime in AD patients.
Instead, clinical testing is still regarded as the standard
tool to diagnose AD. However, especially at the prodromal
AD stage of mild cognitive impairment (MCI) and even at
the dementia stage of this disease, clinical testing lacks
accuracy to establish a reliable AD diagnosis [3, 4]. This
notion has prompted incorporating biomarkers as add-on to
clinical testing into the AD diagnostic workflow [5, 6]. In
this regard, the development of radiotracers to visualize b-
amyloid plaques in vivo in the human brain is an important
and active area of radiopharmaceutical research. b-Amy-
loid imaging agents not only are useful for early AD di-
agnosis [7], but also improve our understanding of the
neuropathogenesis of AD and other neurodegenerative
disorders [8]. Further, the current development of b-amy-
loid-targeted, disease-modifying therapies underscores the
need for imaging biomarkers, as they may facilitate effi-
cacy evaluation of the agent in question [9], as well as
identifying patients who would benefit from therapy [10].
The first experimental positron emission tomography
(PET) tracer used clinically for visual and quantitative
assessment of b-amyloid deposition in the brain was 2-(1-
(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)
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malononitrile ([18F]FDDNP) [11]. Subsequently, the carbon-
11 [11C]-labeled ‘‘thioflavin T’’ derivative, N-methyl-[11C]2-
(4-methylaminophenyl)-6-hydroxybenzothiazole, also known
as the [11C]Pittsburg B compound or [11C]PiB, was developed
[7]. However, the 20-min radioactive half-life of 11C restricts
the use of [11C]PiB to centers with an onsite cyclotron and
extensive radiochemistry infrastructure. A fluorine-18
[18F]-labeled molecule with a radioactive half-life of 110 min
is preferable, as it allows widespread distribution to PET
centers without cyclotron, as is currently the case with
[18F]fluorodeoxyglucose.
Florbetaben is an 18F-labeled polyethylene glycol stil-
bene derivative with high in vitro affinity and specificity
for b-amyloid plaques. A comprehensive clinical devel-
opment program was performed including a pivotal phase
III study (for histological confirmation) and the pooled read
of images, derived from the different clinical studies, as
well as clinical safety and supportive efficacy data gener-
ated in individuals with Down’s syndrome (DS), AD de-
mentia, other dementias, MCI, and in healthy individuals of
varying ages. These studies generated a dataset on which
the overall safety of florbetaben and its diagnostic accuracy
in detecting neuritic b-amyloid plaques in the brain were
substantiated.
This review summarizes and discusses the currently
available knowledge on florbetaben.
Florbetaben tracer characteristics and preclinical data
In vitro, florbetaben shows nanomolar binding affinity to
synthetic b-amyloid fibrils and to AD brain homogenate
[12]. In addition, binding to b-amyloid plaques in post-
mortem AD brain sections was demonstrated by autora-
diography, supported by immunohistochemistry and
Bielschowsky staining. Florbetaben does not bind to tau- or
a-synuclein pathology in human AD, dementia with Lewy
bodies (DLB) or frontotemporal dementia brain tissue,
demonstrating its specificity for b-amyloid deposits
(Fig. 1) [13].
Several studies using human biomaterials were carried
out with radiolabeled florbetaben (tritiated [3H], 14C, and
18F) or the non-radioactive 19F-derivative. Protein-binding
studies were performed with non-radioactive drug sub-
stance in human serum; metabolic stability was tested by
incubation of florbetaben with human plasma and with
human liver microsomes; and human cytochrome P450
(CYP) isoforms involved in the in vitro metabolism of 14C-
florbetaben were investigated and the inhibitory potency of
florbetaben toward human CYP isoforms was tested [per-
sonal communication (Piramal)].
18F-florbetaben was found to be highly bound to plasma
proteins (unbound fraction, 1.6 %), and it is metabolized
by several CYP enzymes. Enzyme CYP4F2 predominantly
mediates N-demethylation, whereas CYP2J2 and CYP3A4
contribute predominantly to the formation of polar
metabolites. Among those, CYP2J2 and CYP4F2 were
identified as the main enzymes involved in the metabolism
of florbetaben. No risk of interactions with CYP enzymes
was identified. Taken together, this preclinical evaluation
indicates that 18F-florbetaben is a promising drug for
imaging b-amyloid plaques typical of AD, as it was shown
to bind to these structures in the brain and has a suitable
pharmacokinetic (PK) profile [personal communication
(Piramal)].
Florbetaben was also shown to be useful in brain b-
amyloid imaging of small experimental animals. In a
mouse model overexpressing Swedish mutant b-amyloid
precursor protein (APP-Swe), 18F-florbetaben uptake was
similar to that in wild-type (WT) mice at 10 and
Fig. 1 Specificity of florbetaben binding. Florbetaben binds
specifically to b-amyloid plaques. High-resolution emulsion autora-
diography using [3H]florbetaben (black) together with immunohisto-
chemical staining for b-amyloid (left), tau (middle), and a-synuclein
(right, each colored in red) in postmortem human brain slices. Co-
localization of the florbetaben signal only with aggregated b-amyloid,
but not with tau- or a-synuclein. Scale bars 15 lm. Reprinted from
Ref. [13], with permission from Elsevier/Society of Radiopharma-
ceutical Sciences
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13 months, but was significantly increased versus baseline
at 16 months (?7.9 %; p \ 0.01) and 20 months
(?16.6 %; p \ 0.001) [14]. There were no temporal
changes in uptake from baseline in WT mice. In a follow-
up study, the same authors demonstrated that applying a
dedicated partial volume effect correction increases the
statistical power for detection of 18F-florbetaben uptake in
aging APP-Swe mice by 10 % [15].
Florbetaben pharmacokinetics
Results from clinical pharmacology studies demonstrate
that, after intravenous bolus injection of 300 MBq flor-
betaben, an 18F-radioactivity concentration of 2–3 % in-
jected dose/L was achieved in arterial plasma 10 min post-
injection (p.i.). Brain radioactivity uptake was rapid,
reaching a maximum of*6 % of injected 18F-radioactivity
at 10 min p.i. Florbetaben was eliminated from the plasma
of patients with AD dementia and healthy controls (HCs;
primarily via the hepatobiliary system) with a mean bio-
logical half-life of *1 h. No relevant radioactivity was
measured in blood at 4 h p.i. [16].
To investigate the influence of ethnicity on the flor-
betaben PK, two clinical studies with identical designs
were performed in healthy Caucasian and Japanese vol-
unteers [16]. Among the secondary objectives were the
comparative evaluation of PK and florbetaben metabolism,
based on a single administration of 300 MBq florbetaben,
with either a low (B5 lg) or high (50–55 lg) tracer mass
dose. PK parameters were evaluated based on the total 18F-
radioactivity in plasma and urine, followed by metabolite
analysis using radio-high-pressure liquid chromatography.
Both ethnic and tracer mass dose differences were
evaluated. Values for the calculated dose-normalized area
under the concentration–time curve from time 0 to last
measurement (AUC0–tlast) were similar between the low
and high doses, as well as between Caucasian and Japanese
individuals. Furthermore, no significant differences in
AUC0–tlast could be detected between the two populations.
Taken together, no differences in the florbetaben PK were
detected between Japanese and Caucasians [16].
Florbetaben dosimetry
18F has a radioactive half-life of 110 min. At 12 and 24 h
p.i., 98.93 and 99.99 % of the activity, respectively, are
physically decayed. Detailed doses for all organs were
assessed for 17 Caucasian healthy volunteers with a mean
body weight of 73.8 kg, and for 18 Japanese healthy vol-
unteers with a mean body weight of 58.8 kg. Dosimetry
calculations were adapted to the adult model for the
Caucasians (with a body weight of 73.7 kg) or to the
15-year-old model for the Japanese (body weight 56.8 kg),
calculated using OLINDA (Organ Level INternal Dose
Assessment) software.
For 18F-florbetaben, the mean effective dose solely
(without CT exposure in case of combined PET/CT) re-
sulting from the administration of 300 MBq to Caucasian
individuals was 5.8 ± 0.42 mSv. For the Japanese indi-
viduals of lower body weight, the mean effective dose was
slightly higher (8.1 ± 0.48 mSv), but still well within the
range of other radiopharmaceutical diagnostic agents [17].
Florbetaben safety
The data submission to the health authorities comprised
safety assessments from 978 administrations to 872 sub-
jects who received florbetaben and 12 who received vehi-
cle. The results show that florbetaben at the recommended
radioactive exposure of 300 ± 20 % MBq and tracer mass
doses of up to 55 lg per injection is generally safe and well
tolerated. As to be expected with a PET tracer such as
florbetaben, no signs of organ toxicity or impaired toler-
ance resulting from pharmacodynamic or pharmacological
drug activity were observed. No significant trends indica-
tive of a safety concern were apparent overall or in sub-
group analyses according to sex, age, region or estimated
glomerular filtration rate. Furthermore, there was no
specific profile for adverse events after the florbetaben PET
application. The most common side effects observed in
clinical trials were injection-site reaction and injection-site
pain [18].
Comparison with [11C]PiB and test–retest variability
of florbetaben
[11C]PiB was compared with florbetaben in 10 healthy
elderly individuals and 10 patients with AD dementia who
had undergone PET imaging after intravenous injection of
370 MBq of [11C]PiB and 300 MBq of florbetaben under
separate research protocols [19]. [11C]PiB and florbetaben
images were processed and analyzed similarly and co-
registered so that placement of regions of interest (ROIs)
was identical on both scans. The results showed that
standardized uptake value ratios (SUVRs), taking the
cerebellum as reference region, were significantly higher
(p \ 0.0001) for both tracers in patients with AD dementia
versus health controls in most cortical areas. Global
SUVRs in patients with AD dementia were on average
75 % higher than in HCs with PiB and 56 % higher with
florbetaben, with an excellent linear correlation between
PiB and florbetaben global SUVRs (r = 0.97, p \ 0.0001)
(Fig. 2a). Effect sizes for distinguishing AD dementia from
Clin Transl Imaging (2015) 3:13–26 15
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HCs were similar for both radiotracers (Cohen’s d: 3.3 for
PiB, 3.0 for florbetaben). Further, the test–retest variability
of *6 % was within acceptable limits [20].
Optimal scan duration for florbetaben
The effect of scan duration on the accuracy of florbetaben
PET was evaluated using data from 25 patients with AD
dementia and 25 healthy volunteers [21]. In each par-
ticipant, scans of 5, 10 and 20 min duration were analyzed,
all starting at 90 min p.i. Visual assessment was conducted
by three blinded experts, and the presence or absence of b-
amyloid, and diagnostic confidence (0–100 %) were
scored. Randomly selected datasets of 10 patients with AD
dementia and 10 healthy volunteers were quantified using
an established volume of interest (VOI)-based approach
and a voxel-based approach. The sensitivity and specificity
of the blinded read were each (for three independent
blinded readers) 80 and 96 %, respectively, for all scan
durations, with diagnostic confidence of 95 ± 8, 97 ± 6
and 97 ± 6 % for the 5-, 10- and 20-min scans, respec-
tively. Inter-reader agreement was high (kappa =
0.89–0.94), and intra-reader agreement was significantly
higher for the 20-min scan (kappa = 1.00) than the 5- and
10-min scans (kappa = 0.80 [p = 0.003] and 0.71
[p = 0.002], respectively). For all scan durations, com-
posite SUVRs (Cohen’s d effect size: 3.9–4.5; all
p \ 0.0001) (Fig. 3) and individual brain volumes affected
by b-amyloid (Cohen’s d effect size: 1.6–2.0; all
p \ 0.005) were significantly higher in patients with AD
dementia versus HCs. From this study it was concluded
that in cases in which the recommended scan duration of
20 min (starting 90 min after tracer administration) is not
realistic due to the patient’s inability to cooperate (a feature
that might occur quite often, especially in the target
population of dementia patients), a reduction of the scan
duration is possible for florbetaben without losing diag-
nostic accuracy [21].
Florbetaben efficacy evaluation for b-amyloid detection
Throughout a comprehensive phase 0–III clinical devel-
opment program, the efficacy of florbetaben was estab-
lished for detecting neuritic b-amyloid plaques by means of
PET imaging. These trials employed different standards of
truth (SoTs) depending on the clinical scenario. In one
scenario, clinical diagnosis of AD dementia served as the
SoT, given that b-amyloid plaques are one hallmark of AD.
In another instance, clinical diagnosis of Down’s syndrome
(DS) was employed as the SoT, given that the brains of
patients with DS will, at certain ages, inevitably experience
pathological b-amyloid plaque accumulation. In another
scenario, progression toward dementia in MCI served as
the SoT. Finally, and most importantly, postmortem his-
topathology for b-amyloid plaques served as the ultimate
SoT in the pivotal phase III trial. The following paragraphs
summarize the results of these florbetaben efficacy trials.
Proof-of-concept studies
The first-in-human study evaluating florbetaben (then
known as BAY94-9172) for its potential to image neuritic
b-amyloid plaques in AD dementia patients was carried out
in Australia by Rowe et al. in 2008 [22]. In this study, 15
AD dementia patients and 15 HCs, as well as five patients
Fig. 2 18F-florbetaben binding can be accurately quantified by PET
imaging. Intra-individual comparison between 18F-florbetaben and the
gold standard amyloid PET tracer (11C-PIB). Standardized uptake
value ratios (SUVRs) showing close positive, linear correlation (a),
and between 18F-florbetaben SUVRs and distribution volume ratios
(DVRs) as obtained by the gold standard method to quantify PET
tracer binding (full kinetic modeling, in this case performed using the
multilinear reference tissue model [MRTM]), again showing a close
positive linear correlation (b). a Reproduced from Ref. [19] 2013
BMJ Publishing Group Ltd. b This research was originally published
in Ref. [24], copyright by the Society of Nuclear Medicine and
Molecular Imaging, Inc
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with frontotemporal lobe degeneration (FTLD), were sub-
jected to florbetaben PET imaging. High discriminative
power was observed for both visual and quantitative PET
data obtained: all AD dementia patients were scored as
positive for Ab, 13 of the 15 HCs as Ab-negative, and all
FTLD patients as Ab-negative in the visual analysis. The
quantitative analysis was consistent with the visual
assessment demonstrating that neocortical tracer uptake
was significantly higher for the AD dementia patients
compared to HCs (SUVR 2.0 ± 0.3 vs. 1.3 ± 0.2;
p \ 0.0001) [22].
As a follow-up proof-of-concept study in Europe, a
similar phase 0 study was carried out in 2008 in Ger-
many. Here, 10 patients with probable AD dementia and
10 age-matched HCs received a single dose of 300 MBq
florbetaben. PET data at 70–90 min p.i. were analyzed
visually by three blinded experts, with quantitative
assessment performed via magnetic resonance imaging
(MRI)-based anatomical sampling of predefined VOIs and
calculation of SUVRs [23]. Individual ‘‘whole-brain b-
amyloid load’’ was calculated by single-case voxelwise
analysis. Based on visual PET analysis, 9/10 patients with
AD dementia, but only 1/10 HCs, were b-amyloid posi-
tive (p = 0.001). Inter-reader agreement between the
three experts was high (weighted kappa C 0.88). Neo-
cortical SUVRs were significantly higher in patients with
AD dementia than in HCs; effect size was largest in the
frontal cortex and smallest in the parietal cortex
(p = 0.003–0.010) and was confirmed by voxel-based
group comparison.
In the above trial, full kinetic modeling, including
dynamic PET imaging and arterial blood sampling, was
employed to fully characterize the [18F]florbetaben phar-
macokinetics in the brain [24]. Regional brain-tissue
time–activity curves for 90 min were analyzed by one-
and two-tissue-compartment (1TCM and 2TCM) models,
with metabolite-corrected plasma data estimating the
specific distribution volume (VS) and distribution volume
ratio (DVR). DVR was also estimated using a multilinear
reference tissue model (MRTM) with cerebellar cortex as
the reference tissue. SUVRs were calculated at 70–90 min
p.i. Results showed that the time–activity curves for all
brain regions were best described by 2TCM. b-amyloid-
binding parameters in the cerebral cortex were sig-
nificantly increased in patients with AD dementia
(p \ 0.05), and there were significant linear correlations
among these parameters (r2 = 0.83). Effect sizes in group
discrimination between the b-amyloid-positive AD de-
mentia scans and the b-amyloid-negative HC scans for all
binding parameters were largest for DVR (2TCM) (4.22)
and smallest for VS (3.25), and intermediate and the same
for DVR (MRTM) and SUVR (4.03). Mean SUVRs
(1.52 ± 0.32) were 12 % higher than the mean DVR
(MRTM) values (1.36 ± 0.25), and there was also a
strong linear relationship between the SUVRs and DVR
(MRTM) values (r2 = 0.90, p \ 0.0001; Fig. 2b). These
data provide the rationale for using SUVRs in future
clinical routine application of [18F]florbetaben as a
quantitative b-amyloid plaque readout, showing only a
small bias toward overestimating b-amyloid binding.
Fig. 3 18F-florbetaben PET
scan duration is flexible.
Transverse PET slices of an
Alzheimer’s disease patient
(upper row) and of a healthy
control (lower row) of different
scan durations, all starting
90 min after tracer
administration. No relevant loss
of image quality and
discrimination ability reducing
scan time from 20 to 10 min or
5 min. Reprinted from ref. [21],
2013 BMJ Publishing Group
Ltd
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Florbetaben to assist in the diagnostic evaluation
of patients with different dementing diseases
This study was carried out to investigate the performance
of florbetaben in different dementia entities. Cortical de-
position of b-amyloid assessed by florbetaben PET was
compared in 32 HCs, 20 individuals with MCI, 30 patients
with AD dementia, 11 with FTLD, seven with DLB, five
with Parkinson’s disease (PD), and four with vascular de-
mentia (VaD) [25]. All participants underwent PET be-
tween 90 and 110 min p.i. after intravenous injection of
300 MBq of florbetaben, and SUVRs were calculated using
the cerebellar cortex as a reference region. Overall, patients
with AD dementia had significantly higher neocortical
SUVRs compared with the other groups (all p \ 0.0001;
Fig. 4). Almost all patients with AD dementia (96 %) and
60 % of those with MCI showed diffuse cortical flor-
betaben retention, compared with 9 % of patients with
FTLD, 25 % of those with VaD, 29 % of those with DLB,
and 16 % of HCs. No patient with PD showed cortical
binding [25]. The data of differential probability and de-
gree of florbetaben binding in different dementia entities
are in accordance with postmortem b-amyloid histo-
pathology and in vivo [11C]PIB PET imaging data in dif-
ferent dementia forms, and suggest that florbetaben PET
might have a future role for differential dementia
diagnosis.
Phase II studies using clinical AD dementia diagnosis
as SoT
The phase II study was a multicenter, open-label, non-
randomized, clinical study in patients with probable AD
dementia and healthy volunteers from Europe and the USA
[26]. Participants were male and female patients of any
ethnicity with the features of probable AD dementia, and
cognitively non-impaired HCs. The clinical diagnosis
served as the SoT in this study; importantly, pathology
examinations have shown that clinical diagnosis can be
wrong (i.e., individuals diagnosed with AD dementia who
do not show b-amyloid plaques upon autopsy) in 10–30 %
of cases [4]. This can lead to false-negatives compromising
the sensitivity estimation.
The phase II study consisted of two parts: an exploratory
part A (n = 150) and a confirmatory part B (n = 272). The
main purpose of Part A was to assess and refine PET scan
acquisition and assessment techniques, compare different
imaging time points, develop a visual assessment algo-
rithm, and develop a quantitative assessment tool (an op-
erator-independent, MRI-segmented, automated template
for SUVR generation) [26]. Clinical diagnosis was estab-
lished by the on-site investigator. In this trial, florbetaben
PET imaging was carried out in 18 centers in Australia,
Germany, Switzerland, and the USA. Altogether, 81 pa-
tients with mild-to-moderate probable AD dementia and 69
age-matched HCs were included. Florbetaben uptake in
neocortical regions was visually scored by three indepen-
dent blinded readers, and quantified using SUVRs deter-
mined from pre-established VOIs on the individual gray-
matter-segmented PET/MRI data.
The blinded read of the 90- to 110-min p.i. florbetaben
PET data resulted in a sensitivity of 80 % (95 % confi-
dence interval (CI) 71–89 %) and a specificity of 91 %
(95 % CI 84–98 %) in discriminating between the two
subject cohorts, which was achieved with high inter-reader
agreement (Fig. 5). With regard to the PET image quan-
tification, the SUVRs were significantly higher for the AD
dementia patients as compared to the HCs in different
neocortical brain regions. Highest effect size for group
discrimination was observed for the posterior cingulate
Fig. 4 18F-florbetaben binding differs between different dementia
types. Varying composite neocortical standardized uptake value ratios
(SUVRs) in groups of healthy controls (HC), patients with Parkin-
son’s disease (PD), dementia with Levy bodies (DLB), mild cognitive
impairment (MCI), Alzheimer’s disease dementia (AD), frontotem-
poral lobar degeneration (FTLD), and vascular dementia (VaD). This
research was originally published in ref. [25], copyright by the
Society of Nuclear Medicine and Molecular Imaging, Inc
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(Cohen’s d 1.49). A linear discriminant analysis of the
quantitative PET data resulted in a sensitivity of 85 % and
a specificity of 91 % for the discrimination between AD
dementia patients and HCs. It was also found that in AD
dementia patients with Ab-positive PET scans (according
to blinded read), APOE e4 alleles were more frequent than
in Ab-negative AD dementia patients. A similar tendency
was observed for the HCs. During this trial, no safety or
tolerability problems were observed for florbetaben PET
imaging [25]. In conclusion, this largest and first global
trial on an 18F-labeled Ab-targeted PET tracer provided in
a multicenter, multi-camera setting evidence for the effi-
cacy, safety and biological (tracing b-amyloid plaques)
relevance of florbetaben PET. In a population representa-
tive of a clinical routine situation, the florbetaben PET data
could be reliably assessed on both a visual and quantitative
basis, as well as quantified in an objective manner.
As a follow-up to this trial, the (mainly unchanged)
design from Part A was applied to Part B of the study
(n = 272), which had a broadened geographic scope with
the inclusion of Japanese patients in addition to those from
Europe, the USA, and Australia. As the two main study
design differences, the SoT in the phase IIB study was
clinical diagnosis established by a panel of experts, and the
PET images were visually scored by five non-Ab-PET-
expert nuclear physicians after running a web-based
training program. PET data of 116 patients with probable
AD dementia (age C55 years, mini-mental state examina-
tion score 18–26, clinical dementia rating 0.5–2) and of
120 cognitively normal elderly volunteers were scored. For
the five blinded readers, sensitivity for discrimination be-
tween AD dementia patients and healthy volunteers ranged
from 69.0 % (95 % CI 60.6–77.4 %) to 81.0 % (95 % CI
73.9–88.2 %), with a median value of 78.5 %, and speci-
ficity ranged from 81.7 % (95 % CI 74.7–88.6 %) to 95 %
(95 % CI 91.1–98.9 %), with a median value of 89.2 %.
Inter-reader agreement was substantial to almost perfect
with a kappa of 0.81 (95 % CI 0.77–0.86) across the five
readers. These results also led to the conclusion that the
training procedure developed leads to accurate and repro-
ducible visual assessments of florbetaben PET data [27].
In conclusion, the two clinical phase II studies con-
firmed the initial efficacy findings of the phase 0 studies in
a larger study population including individuals of varying
age and different race. Based on the results, technical pa-
rameters could be defined for the phase III program: Part A
results were the basis for a re-definition of the rules for the
dichotomized decision, for a positive PET scan result
(‘‘abnormal’’) or a negative PET scan result (‘‘normal’’),
corresponding to b-amyloid present ‘‘yes’’ or ‘‘no’’. The
Fig. 5 18F-florbetaben PET detects Alzheimer’s disease with high
sensitivity and specificity. PET images (upper row) and PET/MRI
overlay (lower row) of two paradigmatic cases: a a patient with
Alzheimer’s disease dementia, b a healthy control individual, imaged
within a worldwide multicenter trial. While in the healthy control,
only unspecific uptake in the white matter was observed, this
extended to the outer gray matter in the Alzheimer’s disease dementia
patient. Reprinted from ref. [26], Copyright (2011) with permission
from Elsevier
Clin Transl Imaging (2015) 3:13–26 19
123
Part B results helped to identify potential bias risks for the
visual assessment algorithm. Consequently, a refined
training program, including the development of an elec-
tronic training tool, was developed for future use and for
further assessment in the phase III program.
Phase II study in individuals with Down’s syndrome
The objective of this study was to investigate brain b-
amyloid binding in 39 individuals with DS (mean age
46.3 ± 4.7 years) using 18F-florbetaben PET imaging [28].
Three blinded independent readers assessed the scans to
provide a visual analysis. The primary quantitative imaging
outcome was SUVR for six brain regions. Cognitive status
was evaluated using the Dementia Screening Questionnaire
for Individuals with Intellectual Disabilities (DSQIID).
Florbetaben uptake was correlated with age: the percentage
of scans visually assessed as positive was 90 % in par-
ticipants aged C50 years (SUVR 1.62 ± 0.26); 53 % in
those aged 45–49 years (SUVR 1.43 ± 0.16); and 7 % in
those aged 40–45 years (SUVR 1.27 ± 0.11) (Fig. 6).
Mean DSQIID score was 6.2 ± 8.0, and there was a sig-
nificant relationship between b-amyloid and subtle cogni-
tive changes (DSQIID scores[ 0). Visual and quantitative
assessments were highly correlated (v2 = 11.3823;
p = 0.0007; Cohen’s kappa 0.58) [28]. In conclusion, brain
b-amyloid binding, as measured by 18F-florbetaben, in-
creases with age in DS. Individuals with DS and no
evidence of dementia demonstrate brain b-amyloid binding
in vivo, suggesting that 18F-florbetaben PET imaging may
detect b-amyloid in this at-risk population.
Pivotal phase III postmortem histopathology study
In October 2008, the clinical usefulness of b-amyloid-tar-
geted PET tracers for detection of pathological states was
verified during a US Food and Drug Administration (FDA)
Central Nervous System Advisory Committee meeting, and
subsequently confirmed by the FDA. During this process, it
was also concluded that, for PET tracers of this type,
postmortem histopathology was the most appropriate SoT
to obtain regulatory approval for an indication such as
‘‘detection of neuritic b-amyloid deposition in the brain.’’
Given this regulatory authority view, a phase III study
was initiated in 2009 for florbetaben designed as an open-
label, non-randomized study to evaluate the efficacy and
safety of florbetaben PET imaging for the detection or
exclusion of cerebral b-amyloid using postmortem brain
histopathology as the SOT. Individuals with a low prob-
ability of cerebral b-amyloid deposition (e.g., volunteers
without dementia) and individuals with a high probability
of b-amyloid deposition (e.g., diagnosis of AD dementia or
DLB) were included in the trial. Determination of the
presence or absence of florbetaben uptake in the PET scan
was compared with postmortem histopathology, and was
enriched with PET scan results from healthy volunteers
Fig. 6 18F-florbetaben PET is
positive in age-dependent
fashion in Down’s syndrome.
Transverse PET slices of a b-
amyloid plaque-negative
healthy control individual
(upper row), together with those
of a 43-year-old patient with
Down’s syndrome who was
scored as b-amyloid plaque-
negative (middle row), and
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who served as additional negative controls. The study was
conducted at 15 study centers: one in Australia, two each in
France and Germany, three in Japan, and seven in the USA.
Of the 253 subjects screened for study participation, 216
received florbetaben.
To provide the strongest possible level of evidence, the
phase III study was designed to demonstrate that flor-
betaben PET imaging during life can detect the presence or
absence of b-amyloid aggregates in precisely the same
location as shown in the postmortem histopathological
examination. This study provided a more rigorous design to
demonstrate that florbetaben PET imaging identifies b-
amyloid deposition precisely where noted in the brain by
pathology (‘‘target validation’’) compared with other
evaluations which used global assessments by the readers
compared with global assessment by pathology. In this
latter design, it is possible to have discordance between the
read and the SOT on a regional basis, but agreement
globally. It is important to emphasize that the regional
tissue-matched florbetaben scan reading method designed
for this endpoint with the consensus panel histopathology
assessment was not primarily intended to reflect or be used
in clinical practice. It was developed to provide evidence
that florbetaben binds specifically to b-amyloid plaques,
proven by consensus panel histopathological assessment of
almost identical tissue-matched regions.
For the regional tissue-matched assessment,
photodocumentation of each postmortem brain specimen
was used to identify the same region on in vivo MRI im-
ages, and finally for co-registration of those with in vivo
florbetaben PET images. A rectangular ROI of the matched
size and location of the tissue samples used for pathology
assessment was then placed on the co-registered PET im-
ages. This ensured that the regions visually assessed on the
florbetaben scans corresponded almost exactly with the
size and location of the tissue samples assessed by the
pathologists during autopsy. Readers were instructed to
visually assess only the florbetaben gray-matter uptake
pattern within the rectangular tissue-matched ROIs. The
scan slices containing the rectangular tissue-matched ROIs
were presented to the blinded readers in a random se-
quence, both across brains and across regions (i.e., the six
regions of one patient were not presented together, but all
regions across all patients were presented to the readers in a
random fashion to diminish potential bias). Thus, no as-
signment of a region to an individual brain was possible.
Readers were required to classify the florbetaben gray-
matter uptake pattern within each of these small rectan-
gular ROIs in a binary fashion: present (‘‘yes’’) or absent
(‘‘no’’). Readers were extensively trained on the rules for
this decision before the reading sessions. A ‘‘positive’’ scan
(abnormal; uptake ‘‘yes’’) should have a gray-matter up-
take equal to or higher than the adjacent non-specific
white-matter uptake. A PET scan was scored ‘‘negative’’
(normal; uptake ‘‘no’’) if uptake in the gray matter was
lower than the adjacent white-matter uptake.
The six regions chosen for the matched scan and his-
topathology included regions known to show high and low
b-amyloid burden within the same individual: middle
frontal gyrus, striatal and parastriatal areas of the occipital
cortex, anterior cingulate cortex, hippocampus, posterior
cingulate–precuneus, and cerebellum. The postmortem
samples of these six regions were examined for the pres-
ence of neuritic and diffuse b-amyloid plaques using a
combination of modified Bielschowsky silver staining and
immunohistochemistry. For the primary efficacy analysis,
31 deceased individuals and 10 young healthy volunteers
were evaluated (41 individuals 9 6 regions per indi-
vidual = 246 brain regions; two regions were not evalu-
able for technical reasons, yielding 244 evaluable regions).
The 10 healthy volunteers were included because the high
age of the end-of-life patients led to difficulties in acquiring
a sufficient number of end-of-life b-amyloid-negative in-
dividuals for the specificity cohort. It is important to note
that this methodology was developed and applied only for
this regional tissue-matched analysis as a target validation
study, and was not applied in a subsequent clinically ap-
plicable whole-brain visual assessment.
The primary endpoint demonstrated a high correlation
between florbetaben accumulation and presence of b-
amyloid in multiple regions of the brain in which matched
comparison was performed. A high level of inter-reader
agreement was achieved for all brain ROIs (kappa = 0.66).
Of 106 ROIs, 82 were read as true PET positive, and 130 of
138 ROIs as true PET negative. In areas known to show b-
amyloid plaques more frequently in AD (frontal cortex,
anterior cingulate, posterior cingulate/precuneus area),
tissue-matched ROI sensitivity was 82–90 % and speci-
ficity was 86–95 %. Sensitivity was lower (57 %) but
specificity higher (100 %) for the hippocampus, resulting
in an overall sensitivity of 77.4 % (95 % CI 65.3–89.4 %)
and a specificity of 94.2 % (95 % CI 88.6–99.8 %) for all
ROIs. In the tissue-matched ROI quantitative florbetaben
PET assessment, significantly higher SUVRs were found
for regions confirmed to have histopathological evidence of
b-amyloid compared with regions that were scored nega-
tive for b-amyloid, with the exception of the hippocam-
pus/parahippocampal gyrus, consistent with the visual
assessment suggesting that the unique anatomy of this re-
gion including potential partial volume errors limits the
reliability of PET assessment.
To better reflect future clinical use of florbetaben and
similar to other b-amyloid PET histopathology studies,
PET scan reads on a subject-level (whole-brain) basis were
investigated as a secondary endpoint to determine the
sensitivity and specificity of florbetaben in this setting.
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Results from the visual assessment using the method ap-
plicable for clinical use were compared with the neu-
ropathological assessment of the absence/presence of b-
amyloid plaques according to the criteria of the Consortium
to Establish A Registry for Alzheimer’s Disease (CERAD).
This analysis is crucial, as it reflects the expected efficacy
of florbetaben in clinical practice. The aim of this part of
the phase III study was to evaluate the diagnostic perfor-
mance using the whole brain visual assessment method
proposed for clinical use. This read was done on flor-
betaben scan images alone without MRI co-registration.
After in-person training, three independent readers blinded
to clinical and pathology data read all PET images included
in the study. The whole brain results of the first 31 de-
ceased individuals and the 10 young healthy volunteers
were included in the interim analysis. The visual assess-
ment method designed for this part of the study was sub-
sequently used in studies aiming to assess the efficacy of
the florbetaben scan reading by means of an electronic
training tool.
In an interim analysis, results of the whole brain
assessments included as secondary endpoints were con-
sistent with the overall primary efficacy findings. Visual
assessment of florbetaben PET images according to re-
gional cortical tracer uptake (RCTU)/regional cortical
tracer binding (RCTB) scoring and brain b-amyloid plaque
load (BAPL) scoring compared with the on-site neu-
ropathological assessments according to CERAD (as SoT)
showed a sensitivity of 100 % (95 % CI 80.49–100 %), a
specificity of 91.67 % (95 % CI 80.61–100 %), and a near-
perfect inter-reader agreement (kappa = 0.870).
Results from the interim analysis were subsequently
confirmed in a larger cohort and included in EU and US
regulatory submissions. The whole brain results of the
final analysis, performed on all evaluable brains, were
similar to those of the interim analysis. Results for the
European Medicines Agency (EMA) and FDA subsets
(74 and 82 deceased individuals, respectively, who were
available at the respective time points) were similar to
the main results. The results from the ‘‘EMA set’’
(n = 74), using the majority read of three in-person
trained readers compared with onsite neuropathology, are
included in the Summary of Product Characteristics
(SmPC) (sensitivity: 97.87 [95 % CI 93.75–100 %];
specificity 88.89 (95 % CI 77.03–100 %) [18]. The re-
sults from the ‘‘FDA set’’ (n = 82), using neu-
ropathology consensus panel-based SoT, are included in
the US Prescribing Information. The ranges among the
three readers were 96–98 % for sensitivity and 77–83 %
for specificity [29]. Moreover, the addition of young
healthy volunteers was no longer needed, as a suffi-
ciently high number of b-amyloid-negative individuals
became available for the analyses.
MCI study
Amyloid PET, in the above-described AD biomarker sce-
nario, is considered a valuable tool to increase confidence in
understanding the pathophysiological relatedness of MCI and
AD [30]. To investigate the potential of florbetaben in pre-
dicting AD dementia in MCI subjects, a longitudinal study
was designed. In this study, the clinical utility of b-amyloid
imaging with florbetaben was assessed in individuals with
MCI suspected due to AD and with delayed paragraph recall
as an inclusion criterion [31–33]. Florbetaben prognostic
accuracy was evaluated for progression to AD dementia by
comparing semi-quantitative and visual scan assessments,
and by exploring the relationships between b-amyloid, hip-
pocampal volume, and memory over time.
Forty-five individuals with MCI underwent florbetaben
PET, MRI, and neuropsychological assessment at baseline and
2 years, with clinical follow-up at 4 years. Positive florbetaben
scans, defined by a cortical-to-cerebellar cortex uptake ratio
(SUVR) C1.45, were compared with visual assessment by five
readers. Amnestic MCI (aMCI) was defined by a composite
episodic memory (EM) Z score below -1.5.
At baseline, 24 (53 %) individuals with MCI were posi-
tive for florbetaben PET [31]. Majority reads agreed with
SUVR classification (kappa = 0.96). After 2 years, 18
(75 %) florbetaben PET-positive individuals had progressed
to AD dementia compared with two (9.5 %) florbetaben
PET-negative individuals, yielding a predictive accuracy of
83 % [95 % CI 61–94 %] [32] (Fig. 7). Four florbetaben
PET-negative individuals developed non-AD dementia.
Predictive accuracies of hippocampal volume (58 % [95 %
CI 42–73 %]) and aMCI status (73 % [95 % CI 58–81 %])
were lower, and combinations did not improve accuracy. At
4 years, 21 (87.5 %) florbetaben PET-positive individuals
had AD dementia whereas five (24 %) florbetaben PET-
negative individuals had non-AD dementia, yielding a pre-
dictive accuracy of 94 % (95 % CI 74–99 %). While the
strong baseline association between florbetaben SUVR and
EM declined over 2 years, the association between EM and
hippocampal volume became stronger. Florbetaben SUVR
increased by 2.2 %/year in florbetaben PET-positive indi-
viduals, with no change in florbetaben PET-negative indi-
viduals. In conclusion, 18F-florbetaben b-amyloid imaging
facilitates accurate detection of prodromal AD. As neu-
rodegeneration progresses, and in contrast with the early
stages of the disease, hippocampal atrophy—not b-amy-
loid—seems to drive memory decline.
Florbetaben PET image acquisition and analysis
In future clinical routine use of florbetaben, potential
readers will need to undergo an a priori training program.
22 Clin Transl Imaging (2015) 3:13–26
123
For that purpose, a web-based florbetaben reader training
tool was developed. Figure 8 demonstrates key features
that are communicated in this tool to future florbetaben
readers.
A recent investigation assessed the reproducibility (in-
ter- and intra-reader agreement) of the visual assessment of
PET scans after completing this web-based florbetaben
reader training program from a patient population that
closely represents the future clinical use population. 18F-
florbetaben PET scans were pooled from clinical studies
and randomly assigned for consecutive, blinded visual
assessment by five independent blinded nuclear medicine
physicians. In total, 461 18F-florbetaben injections from
phase I–III clinical trials were included in the analysis.
Images were acquired from patients with diagnoses of
probable and possible AD dementia (mild to moderate),
other dementia subtypes, and MCI, and from healthy vol-
unteers. Readers had limited or no prior experience with b-
amyloid PET visual interpretation and were trained on an
electronic training tool; 10 % of images were randomly re-
presented to readers for the assessment of intra-reader
agreement. The primary endpoint showed a kappa value of
0.787 (95 % CI 0.750–0.824) across all five readers. The
inter-reader agreement was high in all reader pairs, ranging
from 0.677 (95 % CI 0.609–0.744) to 0.865 (95 % CI
0.819–0.911). In conclusion, a computer-based web train-
ing tool provides high inter- and intra-rater reliability and
efficacy in the visual assessment of 18F-florbetaben PET
among inexperienced readers of scans from a clinically
relevant patient cohort.
General recommendations on how to acquire and ana-
lyze florbetaben and other b-amyloid tracer PET images
will soon be published as Amyloid PET Procedure
Guidelines jointly developed by the Society of Nuclear
Medicine and the European Association of Nuclear
Medicine.
As specified in the EU SmPC, 18F-florbetaben PET im-
ages are read in a transaxial orientation using a gray scale
[18]. The reader should compare the cortical gray-matter
signal intensity to the maximum white-matter signal inten-
sity in a systematic manner, starting at the cerebellum and
scrolling up through the lateral temporal and frontal lobes,
then to the area of the posterior cingulate cortex and pre-
cuneus, and finally to the parietal lobe. Interpretation of the
images is made visually comparing the activity in cortical
gray matter with activity in adjacent cortical white matter.
Each of these brain regions—lateral temporal cortex, frontal
cortex, posterior cingulate cortex/precuneus, and parietal
cortex—should be systematically visually assessed and
scored according to the RCTU and BAPL scores. The RCTU
scoring system grades the tracer uptake in each of the above
regions as 1 = no binding, 2 = minor binding, and
3 = pronounced binding. The RCTU scores for the frontal
cortex, posterior cingulate cortex/precuneus; lateral tempo-
ral cortex, and parietal cortex are then condensed into a
single three-grade scoring system for each PET scan; the
BAPL score: 1 = no b-amyloid load, 2 = minor b-amyloid
load, 3 = significant b-amyloid load. BAPL scores of ‘‘1’’
are classified as ‘‘b-amyloid-negative PET scan’’, and BAPL
scores of ‘‘2’’ and ‘‘3’’ as ‘‘b-amyloid-positive PET scan’’
(for more details, see florbetaben SmPC [18]).
Impact of florbetaben on diagnostic confidence
and economic implications
Diagnostic confidence was evaluated as an add-on to the
phase IIB study, with a questionnaire given to referring
Fig. 7 18F-florbetaben PET predicts outcome in mild cognitive
impairment (MCI). Composite neocortical standardized uptake value
ratios (SUVRs) in individuals with MCI who, at the 2-year (left) or
4-year (right) clinical follow-up progressed to dementia (dark-gray
circles Alzheimer’s disease, white circles non-Alzheimer’s dementia)
in comparison to those who remained non-demented (light-gray
circles). High predictive power of 18F-florbetaben PET was calculat-
ed. Reproduced from ref. [33], with permission from BMJ Publishing
Group Ltd
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physicians whose patients received florbetaben PET
imaging [34]. The questionnaire consisted of six items
evaluating confidence in the initial clinical diagnosis before
PET results were available, objective results of the flor-
betaben PET scan, congruency of PET imaging and initial
diagnosis, potential change of confidence in the overall
diagnosis based on the PET scan, and the importance and
characteristics of the potential impact on patient manage-
ment. In total, 201 questionnaires were completed (prob-
able AD dementia, n = 121; controls, n = 80). An
increase in confidence in the initial diagnosis after PET was
reported by 80 % of physicians. Imaging results led to an
anticipated impact on intended patient care for 89 % of
patients with AD dementia and 35 % of controls [34].
Guo and colleagues investigated the potential economic
impact of florbetaben PET in the early diagnosis of AD
using a discrete event simulation model [35]. The model
allowed exploratory analyses from US payer and societal
perspectives, simulating the lifetime course of disease
progression and the impact management from initial di-
agnostic workup to final diagnosis. Model inputs were
obtained from a large longitudinal US dataset supple-
mented with data from public data sources and assump-
tions. Model results showed that use of florbetaben PET
was associated with a substantial decrease in the time to
diagnosis. In patients with dementia or pre-dementia,
florbetaben PET was the dominant strategy, resulting in
cost savings alongside increases in quality-adjusted life
years for patients [35].
The results of these two initial studies dealing with the
impact of florbetaben PET imaging on patient care and the
potential economic impact of this new diagnostic tool are
encouraging to further investigate these features, a task of
enormous relevance for future reimbursement discussions
with healthcare system providers.
Conclusions and outlook
The evidence presented in this review shows that flor-
betaben is generally safe and well tolerated. It has a fa-
vorable pharmacokinetics and radiation exposure. Further,
florbetaben has the potential of predicting development of
AD-related dementia in MCI cases and of assisting in the
differential dementia diagnosis. Also, it has high diagnostic
accuracy, as shown employing different gold standards
(from clinical diagnosis to postmortem histopathology), for
the detection of neuritic b-amyloid plaques in the brain. A
negative florbetaben PET scan can reliably exclude AD.
The tracer successfully completed a global multicenter
phase 0–III development program and was, as a conse-





Cerebellar cortex Lateral temporal cortex Frontal cortex 
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Fig. 8 18F-florbetaben PET images are easy to interpret visually by
trained readers. Typical transverse PET slices at different brain levels
of an individual judged as negative for b-amyloid plaques (upper
row) and of an individual judged as positive for b-amyloid plaques
(lower row). Cerebellar cortex serves as a reference region from
which, step-by-step, the evaluation of the four main target regions
(lateral temporal cortex, frontal cortex, posterior cingulate cortex/
precuneus, and parietal cortex) starts. A target brain region is scored
positive for b-amyloid plaques when tracer uptake is not observed
only in white matter (arrows), but also expands toward the outer gray
matter (dashed lines)
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Administration and the European Medicines Agency.
Taken together, florbetaben is a valuable b-amyloid-tar-
geting PET tracer with great potential to serve as a
biomarker supporting clinical AD diagnosis.
Future developments in the field of b-amyloid PET
imaging include the still unsolved role of b-amyloid imaging
in the progression to dementia, the presence of b-amyloid in
healthy elderly individuals, and the use of (semi)-quantifi-
cation in the assessment of b-amyloid load. In addition, there
may also be a role for florbetaben within a combined PET/
MR imaging setup. Here, it is hypothesized that combined b-
amyloid PET/MRI has the potential to provide both pathol-
ogy and neurodegeneration biomarker information in one
step, by supplementing clinical testing to increase certainty
in MCI and AD dementia diagnosis [36]. Also, the potential
of early after-tracer administration florbetaben PET images
as [18F]fluorodeoxyglucose surrogate is currently being in-
vestigated. Further, florbetaben quantification tools are cur-
rently being developed for example to increase PET reader
confidence in rare ambiguous cases or to facilitate follow-up
evaluation after investigational therapeutic interventions.
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